Kestra Medical grew revenue 60% to $31.0M and lifted gross margin 10.8 points to 56.5% on a 9% drop in cost per patient, but a commercial-hiring build-out and a $6.3M debt-refinancing charge widened net loss 71% to $44.1M, leaving roughly 18 months of runway on $244.7M of cash and investments.
Revenue up 60%, gross margin up nearly 11 points — and the loss still widened 71%
Kestra Medical Technologies reported its fiscal first quarter ended July 31, 2026 (the company's fiscal year runs May 1 to April 30, so this quarter covers May–July 2026; the 10-Q was filed September 14, 2026). Revenue grew 60% to $31.0 million and gross profit nearly doubled, but net loss still grew faster than revenue — to $44.1 million — because the company spent an incremental $14.6 million on selling, general and administrative costs and took a $6.3 million accounting charge on refinancing its debt.
Kestra sells one thing: it leases the ASSURE wearable cardioverter defibrillator (WCD) — a vest-style device worn by patients at elevated near-term risk of sudden cardiac arrest, which monitors heart rhythm continuously and delivers a shock automatically when a life-threatening arrhythmia is detected. Revenue is billed on a month-to-month lease directly to Medicare, Medicaid and private insurers rather than to hospitals. There is one operating segment and all revenue is earned in the United States.
Read 0 community reports on Kestra Medical Technologies, Ltd., or write your own.Write a report
Gross margin
56.5%
45.7%
+10.8 pp
Operating expenses (R&D + SG&A)
$55.16M
$37.73M
+46%
Loss from operations
($37.66M)
($28.88M)
30% wider
Operating margin
(121.6%)
(149.1%)
+27.5 pp
Net loss
($44.09M)
($25.83M)
71% wider
Net loss per share (basic & diluted)
($0.75)
($0.50)
50% wider
Weighted-average shares outstanding
58.57M
51.30M
+14.2%
Cost of revenue per patient
—
—
−9% (per MD&A)
Cash used in operating activities
($32.30M)
($26.27M)
23% more burn
Cash, cash equivalents and investments (period end)
$244.7M
—
vs. $262.2M at Apr 30, 2026
"Margin" here means gross margin — the share of each revenue dollar left after the direct cost of building, delivering and servicing the device. "Operating margin" is the same idea one step further down: what's left after research and sales costs too, which for Kestra is still deeply negative.
What actually improved: the unit economics
The gross margin gain is the most substantive thing in this filing, and it is not purely a scale artifact. Cost of revenue rose only 28% against 60% revenue growth, and management attributes that gap to a specific, measurable improvement: cost of revenue per patient fell 9% year over year, which the MD&A credits to "further improvements in the utilization of our rental pool of medical equipment and lower disposable costs driven by volume and implementation of manufacturing cost improvement programs, and longer useful lives of our medical rental equipment components."
Two of those three drivers are durable and one deserves a caveat. Higher rental-pool utilization (getting more patient-months out of the same fleet of returned, reconditioned devices) and lower per-unit disposable costs on higher purchase volumes are real operating leverage. Extending the assumed useful lives of rental equipment components, however, is an accounting estimate change that lowers depreciation expense — the filing quantifies it at a $0.3 million reduction in depreciation within cost of revenue, partially offsetting a $0.9 million increase from having more systems in the field. That's a small contributor, not the story, but it is worth separating from genuine cost-out.
Working against the margin: a $1.1 million increase in the reserve for lost or damaged equipment, the second-largest single increase in cost of revenue. In a business where the asset is physically handed to patients and expected back, unreturned-device losses scale with patient count and are a cost line to keep watching.
Revenue growth itself is attributed simply to "an increase in the number of patients using our products." The filing does not disclose an absolute patient count or a prescriptions figure, so the growth cannot be decomposed here into patient volume versus reimbursement realization versus wear duration — three levers management explicitly names as separate drivers elsewhere in the MD&A.
What got worse: spending grew faster than the revenue it bought
Operating expenses rose $17.4 million, or 46%, to $55.2 million — 178% of revenue.
SG&A (+$14.6 million, +43% to $48.4 million) is the dominant line, and the filing is specific about where it went: $10.7 million of the increase was personnel — salaries, benefits and share-based compensation — "resulting from an increase in headcount to support commercial growth," with smaller increments for contractors ($1.4M), travel ($0.6M), commercial training ($0.6M), shipping and logistics ($0.5M) and software licensing ($0.5M). This is a direct-sales-force build: Kestra is paying reps ahead of the revenue they will eventually produce.
A meaningful share of that "personnel expense" is non-cash. Total share-based compensation was $9.5 million, up from $4.6 million — of which $8.3 million sat in SG&A. So roughly $4.2 million of the $10.7 million SG&A personnel increase is stock compensation, not cash wages. That matters for cash burn (it doesn't consume cash) but it does dilute shareholders, and weighted-average share count is already up 14.2% year over year.
R&D (+$2.8 million, +70% to $6.8 million) grew fastest in percentage terms, on $0.9 million more personnel, $0.9 million more contractor spend, and — notably — $1.0 million of development expense from a strategic collaboration with Biobeat Technologies. That last item is new spend on a partnership rather than incremental headcount, and it is the only sign in this filing of Kestra spending on something beyond the current ASSURE product line.
The encouraging read is that SG&A fell from 174% of revenue to 156%, and total operating expenses from 195% to 178%. The company is getting leverage. The discouraging read is that at a 46% opex growth rate against 60% revenue growth, the absolute operating loss still widened by $8.8 million, and on that trajectory operating breakeven is several years and a great deal of cash away.
The refinancing: a real balance-sheet upgrade with an ugly income-statement footprint
On July 10, 2026, Kestra replaced its Perceptive Term Loan 2024 with a new $200 million facility from BPCR Limited Partnership and BioPharma Credit. The mechanics:
$75 million Tranche A funded immediately; $46.4 million was used to repay the old loan, and after a $3.8 million cash early-termination fee and $3.2 million of issuance costs, net new money was only about $20 million.
Interest rate falls from three-month SOFR + 7.25% to SOFR + 5.50% (with a 3.25% SOFR floor) — a 175 basis point spread reduction, worth roughly $1.3 million a year on $75 million drawn.
Maturity pushed to July 10, 2031, with 48 months of interest-only payments before any principal amortizes. No principal is due until the second fiscal quarter of 2030.
$125 million of additional capacity: a committed $25 million Tranche B available at Kestra's option through July 31, 2027; a committed $50 million Tranche C that unlocks only on reaching $150 million of trailing-twelve-month revenue (requestable through June 30, 2028); and an uncommitted $50 million Tranche D for acquisitions.
A covenant requiring minimum liquidity of $20 million in cash and equivalents at all times. Kestra states it was in compliance as of July 31, 2026.
The accounting cost was a $6.3 million loss on extinguishment of debt — the difference between what Kestra paid to retire the old loan and its carrying value, which includes writing off unamortized discount and issuance costs alongside the $3.8 million cash fee. This charge is the single largest reason net loss grew 71% while operating loss grew only 30%. It is non-recurring.
Strip out both the $6.3 million extinguishment charge and the $2.9 million non-cash warrant gain that flattered the prior-year quarter (the 2033 warrant was marked down in value, producing income; those warrants have since been extinguished as part of this refinancing, and the warrant liability is now zero), and the underlying loss goes from roughly $28.7 million to roughly $37.8 million — about 31% wider, closely tracking the 30% increase in operating loss. That is the cleaner comparison: the headline 71% deterioration overstates what happened to the operating business, and the 50% EPS deterioration understates it only because share count grew.
Note that interest expense was essentially flat year over year ($1.93M vs. $1.91M) despite carrying more debt, and interest income was flat at $2.1 million — Kestra's investment portfolio still earns slightly more than its debt costs.
Cash runway — the number that governs everything
This is a company consuming cash at scale, and the honest arithmetic matters more than the growth rate.
Operating cash burn: $32.3 million for the quarter, up from $26.3 million. The gap between the $44.1 million net loss and the $32.3 million cash burn is explained almost entirely by $19.3 million of non-cash charges — $9.5 million share-based compensation, $6.3 million extinguishment loss, $2.7 million depreciation — partially offset by a $7.5 million working-capital outflow (largely a $4.7 million drawdown of accrued liabilities and $1.9 million of accounts payable).
Capital expenditure: $8.3 million cash on property and equipment — mostly the WCD rental fleet itself, which is capitalized and then depreciated into cost of revenue. Net property and equipment rose to $63.7 million from $59.1 million. Importantly, a further $8.9 million of equipment purchases sat unpaid in accounts payable and accrued liabilities at quarter end, so the accrual-basis fleet investment exceeds the cash number.
Total cash consumption: roughly $40.6 million for the quarter (operating burn plus cash capex).
Liquidity: $244.7 million in cash, equivalents and investments at July 31, down from $262.2 million at April 30 — a decline of only $17.5 million because the refinancing contributed about $20 million net, plus $2.4 million from option exercises and the employee stock purchase plan.
At the Q1 pace of roughly $40.6 million of quarterly cash consumption, $244.7 million is about six quarters, or roughly 18 months, of runway — and about 5.5 quarters if you respect the $20 million minimum-liquidity covenant as a hard floor. Management's own statement is narrower and standard: existing resources are "sufficient to fund our operating and capital needs for at least the next 12 months."
Two things could extend that materially: burn should moderate as a percentage of revenue if the gross-margin trend continues and SG&A growth decelerates below revenue growth, and the committed $25 million Tranche B is available on demand through July 2027. Tranche C's $50 million is further off — it requires $150 million of trailing-twelve-month revenue, and at Q1's $31.0 million quarterly rate the annualized run rate is about $124 million, with trailing twelve months lower still. On current growth, that threshold is plausibly reachable during calendar 2027, but it is not close today.
Accumulated deficit stands at $695.9 million, against $222.4 million of remaining shareholders' equity.
Takeaway: The unit economics are genuinely turning — a 9% reduction in cost of revenue per patient drove gross margin up 10.8 points to 56.5%, and that is the metric that determines whether this business can ever work. But Kestra is deliberately spending that margin improvement, and more, on a commercial build-out: $10.7 million of incremental SG&A personnel cost consumed more than the entire $8.6 million gross profit gain. The company is trading roughly 18 months of runway for market-share capture, and the July refinancing bought time and optionality rather than solving the funding question. Whether that trade works depends entirely on whether SG&A growth falls below revenue growth before the cash does.
What to watch next
Management gave no revenue or earnings guidance in this 10-Q, so there is no company forecast to evaluate here. The forward-looking statements are qualitative: revenue is expected to rise "as the number of patients that use our product increases"; gross profit is expected to improve further on "improved market access and shifts in patient mix towards patients with longer wear duration"; R&D is expected to decline as a percentage of revenue; and SG&A is expected to increase in absolute dollars but decline as a percentage of revenue. Management also flags a specific seasonal drag: billings and collections in January and February run lower because annual insurance deductibles reset, which will fall in Kestra's fiscal Q3 (November–January) and Q4 (February–April).
The three things that will determine the next several quarters:
Does the SG&A growth rate keep falling below the revenue growth rate? This quarter it did — 43% versus 60% — but the absolute gap still widened the operating loss by $8.8 million. The crossover point is when incremental gross profit exceeds incremental opex; it did not happen this quarter.
Does cost of revenue per patient keep declining? A second consecutive high-single-digit decline would confirm that fleet utilization and manufacturing cost programs, not the useful-life estimate change, are doing the work. Gross margin above 60% within a few quarters is the visible test.
Does Kestra draw Tranche B, or return to the equity market? It has raised equity twice already — $215.8 million net at the March 2025 IPO at $17.00, and $149.3 million net in December 2025 at $23.00. A third raise before the 12-month runway statement expires would be the clearest signal that the operating plan is running ahead of the cost curve; drawing the cheaper committed $25 million debt tranche instead would signal the opposite.
My own read on trajectory: the margin curve is the strongest argument for this business, and it is moving in the right direction fast enough to matter. But the loss is still 1.4x revenue, the share count is growing 14% a year, and the runway is measured in quarters rather than years. Absent a sharp deceleration in SG&A growth, another capital raise — most likely dilutive — is more probable than not before fiscal 2028.
Source: Kestra Medical Technologies, Ltd. Form 10-Q for the quarterly period ended July 31, 2026, filed with the SEC on September 14, 2026 (CIK 0001877184, accession 0001193125-26-390766). All figures are from the condensed consolidated financial statements and Management's Discussion and Analysis contained in that filing. Per-quarter runway and annualized run-rate calculations are the author's arithmetic from those figures, not company projections.